A detailed history of Stone Run Capital, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Stone Run Capital, LLC holds 4,100 shares of ABBV stock, worth $719,058. This represents 0.3% of its overall portfolio holdings.

Number of Shares
4,100
Previous 4,600 10.87%
Holding current value
$719,058
Previous $789 Million 2.62%
% of portfolio
0.3%
Previous 0.32%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $81,920 - $99,665
-500 Reduced 10.87%
4,100 $810 Million
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $61,916 - $72,304
-400 Reduced 8.0%
4,600 $789 Million
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $207,766 - $236,730
1,300 Added 35.14%
5,000 $911 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $96,320 - $108,479
-700 Reduced 15.91%
3,700 $573 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $587,796 - $680,460
4,400 New
4,400 $656 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $26,502 - $32,980
200 Added 4.76%
4,400 $592,000
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $14,461 - $16,654
100 Added 2.44%
4,200 $669,000
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $13,831 - $16,587
100 Added 2.5%
4,100 $663,000
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $96,334 - $122,472
-700 Reduced 14.89%
4,000 $612,000
Q4 2019

Feb 14, 2020

SELL
$72.13 - $90.25 $7,213 - $9,025
-100 Reduced 2.08%
4,700 $416,000
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $3,285 - $4,199
-50 Reduced 1.03%
4,800 $349,000
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $62,279 - $76,808
800 Added 19.75%
4,850 $447,000
Q1 2018

May 14, 2018

SELL
$92.01 - $123.21 $23,002 - $30,802
-250 Reduced 5.81%
4,050 $383,000
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $300,355 - $383,646
4,300
4,300 $382,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Stone Run Capital, LLC Portfolio

Follow Stone Run Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone Run Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stone Run Capital, LLC with notifications on news.